| May 22, 2002 |
Unit-Dose Antibacterial Eye drops |
||||||||||||||||||||||
|
||||||||||||||||||||||
On May 23, Taisho Pharmaceuticals Co., Ltd. (President: Akira Uehara) will begin sales of Antibacterial Irisα, a new formulation antibacterial eyedrops that addresses the onset process of sties. Antibacterial Irisα combines the persistent antibacterial agent sodium sulfamethoxazole with glycyrrhizin diacid potassium, an anti-inflammatory agent to sooth the eye’s inflammation or itching, chondroitin sodium sulfate, which protects the cornea, and taurin, which nourishes the eyes. These four types of active principles work effectively on Antibacterial Iris α. Antibacterial Iris α is an 18-piece pack unit-dose type eyedrops, which boasts excellent portability. Antibacterial Iris α does not irritate the eyes. This is why this eyedrops can be used by all the family regardless of age. In March 1993, the Company released Aris CL-I for sale. This is a unit-dose lacrimal eyedrops intended for the use of contact lens or for dry-eye symptoms. In May 1997, another unit-dose eyedrops"Antibacterial Iris" went on sale. Those have has proven highly popular with consumers. |
||||||||||||||||||||||
Product features
|
||||||||||||||||||||||
Product Overview
|